How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT.

Fuji S, Rovó A, Ohashi K, Griffith M, Einsele H, Kapp M, Mohty M, Majhail NS, Engelhardt BG, Tichelli A, Savani BN
Bone Marrow Transplant. 2016 51 (8): 1041-9

PMID: 27042848 · DOI:10.1038/bmt.2016.81

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients frequently develop glucose intolerance and post-transplant diabetes mellitus (PTDM). The clinical importance of PTDM and its detrimental impact on HSCT outcomes are under-recognized. After allo-HSCT, various mechanisms can contribute to the development of PTDM. Here we review information about hyperglycemia and PTDM after allo-HSCT as well as PTDM after solid organ transplantation and describe ways to manage hyperglycemia/PTDM after allogeneic HSCT. Taking into consideration a lack of well-established evidence in the field of allo-HSCT, more studies should be conducted in the future, which will require closer multidisciplinary collaboration between hematologists, endocrinologists and nutritionists.

MeSH Terms (7)

Diabetes Mellitus Disease Management Forecasting Hematopoietic Stem Cell Transplantation Humans Hyperglycemia Transplantation, Homologous

Connections (1)

This publication is referenced by other Labnodes entities: